頻尿,尿失禁に対する塩酸テロジリンの臨床経験

Abstract

頻尿, 尿失禁を主訴とする各種疾患患者に塩酸テロジリンを投与し, 有用性と安全性の検討を行った.1)自覚症状については, 投与4週間で有意差をもって改善を認めた.他覚所見である残尿量についても減少する結果を得た.排尿量, 尿流量率については変化がみられなかった.2)改善効果は患者背景の如何にかかわらず, ほぼ同様であった.3) 37例中に29例に塩酸テロジリンの有用性を認めた.4)副作用は38例中3例に認めたが, いずれも軽度であった.また, 臨床検査上異常変動は認めなかった

Efficacy and safety of terodiline hydrochloride were studied by treating 38 patients who complained of pollakiuria and incontinence with this drug. Terodiline hydrochloride in a dose of 24 mg once or 12 mg twice a day was administered to these patients for 4 weeks and the conditions of the patients before and after the treatment were evaluated. According to the subjective symptoms, pollakisuria during the daytime and at night, incontinence, anischuria at night and frequency of urination were all reduced significantly. Objective symptoms detected after the treatment a tendency of increase (p less than 0.1) in the bladder volume at the time of maximum micturition. However, no change in the urination volume and the maximum urine flow was observed before and after the administration. A significant decrease (p less than 0.05) in residual urine was noted after the treatment. The results were favorable with overall improvement of 78.4% and efficacy of 75.7%. Side effects were observed in 3 of the 38 cases (7.9%), but all the symptoms were slight.